journal article·2019-02-13Open access

Personalized Nanotherapy by Specifically Targeting Cell Organelles To Improve Vascular Hypertension

Rajasekharreddy Pala, Ashraf M. Mohieldin, Kiumars Shamloo, Rinzhin T. Sherpa, Sarmed H. Kathem, Jing Zhou, Zhongyue Luan, Jian-Guo Zheng, Amir Ahsan, Surya M. Nauli

Nano Letters· Volume 19· Issue 2

Abstract

Ciliopathies caused by abnormal function of primary cilia include expanding spectrum of kidney, liver, and cardiovascular disorders. There is currently no treatment available for patients with cilia dysfunction. Therefore, we generated and compared two different (metal and polymer) cilia-targeted nanoparticle drug delivery systems (CTNDDS), CT-DAu-NPs and CT-PLGA-NPs, for the first time. These CTNDDS loaded with fenoldopam were further compared to fenoldopam-alone. Live-imaging of single-cell-single-cilium analysis confirmed that CTNDDS specifically targeted to primary cilia. While CTNDDS did not show any advantages over fenoldopam-alone in cultured cells in vitro, CTNDDS delivered fenoldopam more superior than fenoldopam-alone by eliminating the side effect of reflex tachycardia in murine models. Although slow infusion was required for fenoldopam-alone in mice, bolus injection was possible for CTNDDS. Though there were no significant therapeutic differences between CT-DAu-NPs and CT-PLGA-NPs, CT-PLGA-NPs tended to correct ciliopathy parameters closer to normal physiological levels, indicating CT-PLGA-NPs were better cargos than CT-DAu-NPs. Both CTNDDS showed no systemic adverse effect. In summary, our studies provided scientific evidence that existing pharmacological agent could be personalized with advanced nanomaterials to treat ciliopathy by targeting cilia without the need of generating new drugs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Genetic and Kidney Cyst Diseases · Cerebrospinal fluid and hydrocephalus · Fetal and Pediatric Neurological Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical & Pharmaceutical Sciences, Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, California 92618, United States

Department of Urology, University of California Irvine, Irvine, California 92868, United States

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, United States

Department of Physics, Computer Science & Engineering, Chapman University, Orange, California 92866, United States

Funding

Chapman University · National Heart, Lung, and Blood Institute · U.S. Department of Defense

References (36)

Show source-provided references
1. 10.1002/adma.20150247910.1002/adma.201502479 ↗
2. 10.1021/acsnano.7b0119710.1021/acsnano.7b01197 ↗
3. 10.1016/j.addr.2012.10.00310.1016/j.addr.2012.10.003 ↗
4. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
5. 10.1016/j.biomaterials.2012.03.07710.1016/j.biomaterials.2012.03.077 ↗
6. 10.1002/smll.20040009310.1002/smll.200400093 ↗
7. 10.1126/science.310.5746.21610.1126/science.310.5746.216 ↗
8. 10.1038/nature1426910.1038/nature14269 ↗
9. 10.1161/CIRCULATIONAHA.113.00574610.1161/CIRCULATIONAHA.113.005746 ↗
10. 10.1056/NEJMra101017210.1056/NEJMra1010172 ↗
11. 10.7554/eLife.0699610.7554/eLife.06996 ↗
12. 10.1091/mbc.e07-09-094210.1091/mbc.e07-09-0942 ↗
13. 10.1016/S0006-8993(00)02519-110.1016/S0006-8993(00)02519-1 ↗
14. 10.1016/S0306-4522(98)00354-610.1016/S0306-4522(98)00354-6 ↗
15. 10.1096/fj.15-27494410.1096/fj.15-274944 ↗
16. 10.1161/HYPERTENSIONAHA.111.17208010.1161/HYPERTENSIONAHA.111.172080 ↗
17. 10.1016/j.cub.2009.11.07210.1016/j.cub.2009.11.072 ↗
18. 10.3969/j.issn.1671-5411.2014.01.00110.3969/j.issn.1671-5411.2014.01.001 ↗
19. 10.1016/j.jcis.2013.06.01510.1016/j.jcis.2013.06.015 ↗
20. 10.1161/CIRCRESAHA.108.19276510.1161/CIRCRESAHA.108.192765 ↗
21. 10.1038/nmeth.264710.1038/nmeth.2647 ↗
22. 10.1016/j.atherosclerosis.2018.06.81810.1016/j.atherosclerosis.2018.06.818 ↗
23. 10.1681/ASN.201501001610.1681/ASN.2015010016 ↗
24. 10.1111/j.1476-5381.1995.tb15884.x10.1111/j.1476-5381.1995.tb15884.x ↗
25. Szabo B. · J. Pharmacol. Exp. Ther. · 1986 · 239 · 881
26. 10.1183/13993003.01542-201610.1183/13993003.01542-2016 ↗
27. 10.1371/journal.pone.011971210.1371/journal.pone.0119712 ↗
28. 10.1038/nrneph.2016.13510.1038/nrneph.2016.135 ↗
29. 10.1681/ASN.200610116510.1681/ASN.2006101165 ↗
30. 10.1021/nn404117j10.1021/nn404117j ↗
31. 10.2147/IJN.S3280010.2147/IJN.S32800 ↗
32. 10.1021/nn800072t10.1021/nn800072t ↗
33. 10.1007/s11095-010-0260-110.1007/s11095-010-0260-1 ↗
34. 10.1161/CIRCULATIONAHA.107.71011110.1161/CIRCULATIONAHA.107.710111 ↗
35. 10.1007/s00018-015-1838-x10.1007/s00018-015-1838-x ↗
36. 10.1111/j.1365-2885.2011.01319.x10.1111/j.1365-2885.2011.01319.x ↗